1690307-05-1
Chemical Structure
Obexelimab
Synonym(s): XmAb5871
- CAS No.: 1690307-05-1
- Formula:N/A
- Molecular Weight:(147.24 kDa)
IUPAC Name: (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-(1H-indol-1-yl)-4-(phosphonooxy)tetrahydro-2H-pyran-3-yl 3-methylbutanoate
SMILES: [Obexelimab]
Biological Activity: Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Obexelimab | 99.99% | Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Boyles JS, et al. A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases. JCI Insight. 2023 Jul 10;8(13):e166137. [Content Brief]
- [2]. Chu SY, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014 May;66(5):1153-64. [Content Brief]
- [3]. Horton HM, et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 1;186(7):4223-33. [Content Brief]
Keywords
